Volume 7 Issue 1
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2023  >  7(1): 71-73
Wen Wu, Xiangyan Huang. Ceftazidime-induced immune hemolytic anemia: a case report[J]. Blood&Genomics, 2023, 7(1): 71-73. doi: 10.46701/BG.2023012023002
Citation: Wen Wu, Xiangyan Huang. Ceftazidime-induced immune hemolytic anemia: a case report[J]. Blood&Genomics, 2023, 7(1): 71-73. doi: 10.46701/BG.2023012023002
shu

Ceftazidime-induced immune hemolytic anemia: a case report

doi: 10.46701/BG.2023012023002

  • Department of Transfusion Medicine, the 960th Hospital of the PLA Joint Logistics Support Force, Jinan, Shandong 250031, China

More Information
  • Corresponding author: Xiangyan Huang, Department of Transfusion Medicine, the 960th Hospital of the PLA Joint Logistics Support Force, 25 Shifan Road, Jinan, Shandong 250031, China. E-mail: xiangyan73@aliyun.com
  • Received Date: 2023-01-01
  • Rev Recd Date: 2023-04-21
  • Accepted Date: 2023-05-10
    • Available Online: 2023-06-01
  • Publish Date: 2023-06-30
    Abstract
  • Drug-induced immune hemolytic anemia (DIIHA) is considered a rare condition. Nonsteroidal anti-inflammatory drugs and antineoplastic drugs are the main causes of DIIHA. An 86-year-old male patient with pulmonary infection was admitted to the 960th Hospital of the PLA Joint Logistics Support Force. The patient was treated with ceftazidime in addition to supportive treatment. A history of antibiotics intake and clinical and laboratory hemolysis features were considered to be key bases for DIIHA diagnosis. Clinicians need to be aware of and accurately diagnose this rare complication caused by commonly prescribed drugs to stop the use of causative drugs in time, and therefore, to prevent serious and sometimes fatal consequences.

     

    • FullText(HTML)
  • loading
    • References(6)
  • [1]
    Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes[J]. Immunohematology, 2014, 30(2): 44–54.
    [2]
    Garratty G. Immune hemolytic anemia associated with drug therapy[J]. Blood Rev, 2010, 24(4–5): 143−150. doi: 10.1016/j.blre.2010.06.004
    [3]
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239−245. doi: 10.1038/clpt.1981.154
    [4]
    Choi SH, Koh Y. Ceftazidime for respiratory infections[J]. Expert Opin Pharmacother, 2012, 13(14): 2097−109. doi: 10.1517/14656566.2012.721777
    [5]
    Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime[J]. Blood Transfus, 2014, 12(3): 435−437. doi: 10.2450/2014.0237-13
    [6]
    Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia[J]. Br J Haematol, 2017, 177(2): 208−220. doi: 10.1111/bjh.14654
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (252) PDF downloads(7) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return